SG193280A1 - Oligonucleotide modulators of the toll-like receptor pathway - Google Patents
Oligonucleotide modulators of the toll-like receptor pathway Download PDFInfo
- Publication number
- SG193280A1 SG193280A1 SG2013066220A SG2013066220A SG193280A1 SG 193280 A1 SG193280 A1 SG 193280A1 SG 2013066220 A SG2013066220 A SG 2013066220A SG 2013066220 A SG2013066220 A SG 2013066220A SG 193280 A1 SG193280 A1 SG 193280A1
- Authority
- SG
- Singapore
- Prior art keywords
- seq
- nos
- nucleic acid
- acid molecule
- double stranded
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161448707P | 2011-03-03 | 2011-03-03 | |
| PCT/US2012/027174 WO2012118911A1 (en) | 2011-03-03 | 2012-03-01 | Oligonucleotide modulators of the toll-like receptor pathway |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG193280A1 true SG193280A1 (en) | 2013-10-30 |
Family
ID=45816002
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013066220A SG193280A1 (en) | 2011-03-03 | 2012-03-01 | Oligonucleotide modulators of the toll-like receptor pathway |
| SG10201604479YA SG10201604479YA (en) | 2011-03-03 | 2012-03-01 | Oligonucleotide Modulators Of The Toll-Like Receptor Pathway |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201604479YA SG10201604479YA (en) | 2011-03-03 | 2012-03-01 | Oligonucleotide Modulators Of The Toll-Like Receptor Pathway |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9487778B2 (https=) |
| EP (1) | EP2681315B1 (https=) |
| JP (2) | JP6132775B2 (https=) |
| CN (1) | CN103562387A (https=) |
| AU (1) | AU2012223366B2 (https=) |
| CA (1) | CA2828544A1 (https=) |
| IL (1) | IL228260B (https=) |
| SG (2) | SG193280A1 (https=) |
| WO (1) | WO2012118911A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2631291T3 (da) | 2010-10-22 | 2019-06-11 | Olix Pharmaceuticals Inc | Nukleinsyremolekyler, der inducerer rna-interferens, og anvendelser deraf |
| EP2681314B1 (en) | 2011-03-03 | 2017-11-01 | Quark Pharmaceuticals, Inc. | Compositions and methods for treating lung disease and injury |
| US9796979B2 (en) | 2011-03-03 | 2017-10-24 | Quark Pharmaceuticals Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
| US20130297023A1 (en) * | 2012-05-07 | 2013-11-07 | Hee-Jeong Im Sampen | Methods and Devices For Treating Intervertebral Disc Disease |
| KR101567576B1 (ko) | 2012-05-22 | 2015-11-10 | 올릭스 주식회사 | 세포 내 관통능을 가지고 ｒｎａ 간섭을 유도하는 핵산 분자 및 그 용도 |
| CN103757024B (zh) * | 2014-01-29 | 2015-10-28 | 中国人民解放军第二军医大学 | 一种干扰tlr4受体的小rna及其应用 |
| ES2555160B1 (es) * | 2014-06-24 | 2016-10-25 | Aptus Biotech, S.L. | Aptámeros específicos de TLR-4 y usos de los mismos |
| CN104450710B (zh) * | 2014-11-28 | 2018-06-05 | 广州市锐博生物科技有限公司 | 抑制myd88基因的寡聚核酸及其应用 |
| WO2016141236A1 (en) * | 2015-03-03 | 2016-09-09 | Ionis Pharmaceuticals, Inc. | Compositions for modulating mecp2 expression |
| RS62672B1 (sr) | 2015-04-03 | 2021-12-31 | Univ Massachusetts | Oligonukleotidna jedinjenja za tretman preeklampsije i drugih angiogenskih poremećaja |
| PL3277814T3 (pl) | 2015-04-03 | 2020-11-30 | University Of Massachusetts | Związki oligonukleotydowe ukierunkowane na mrna huntingtyny |
| US20160319278A1 (en) | 2015-04-03 | 2016-11-03 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| WO2017019660A1 (en) | 2015-07-27 | 2017-02-02 | Alnylam Pharmaceuticals, Inc. | Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof |
| WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| WO2017037324A1 (es) * | 2015-09-04 | 2017-03-09 | Servicio Andaluz De Salud | Biomarcadores para la esclerosis lateral amiotrófica (ela) |
| JP7027311B2 (ja) | 2015-11-16 | 2022-03-01 | オリックス ファーマシューティカルズ，インコーポレーテッド | ＭｙＤ８８又はＴＬＲ３を標的とするＲＮＡ複合体を使用した加齢黄斑変性の治療 |
| US10478503B2 (en) | 2016-01-31 | 2019-11-19 | University Of Massachusetts | Branched oligonucleotides |
| JP6944942B2 (ja) | 2016-02-02 | 2021-10-06 | オリックス ファーマシューティカルズ，インコーポレーテッド | ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療 |
| KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
| CA3033368A1 (en) | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
| CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| EP3580339A4 (en) | 2017-02-10 | 2020-12-23 | Research & Business Foundation Sungkyunkwan University | LONG DOUBLE STRAND RNA FOR RNA INTERFERENCE |
| JP7406793B2 (ja) | 2017-06-23 | 2023-12-28 | ユニバーシティー オブ マサチューセッツ | ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法 |
| CA3103429A1 (en) * | 2018-06-14 | 2019-12-19 | Don W. Cleveland | Compounds and methods for increasing stmn2 expression |
| WO2020011869A2 (en) | 2018-07-11 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting tlr2 |
| WO2020033899A1 (en) | 2018-08-10 | 2020-02-13 | University Of Massachusetts | Modified oligonucleotides targeting snps |
| US11279930B2 (en) | 2018-08-23 | 2022-03-22 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| CN113614232A (zh) | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
| KR20220047989A (ko) | 2019-08-09 | 2022-04-19 | 유니버시티 오브 매사추세츠 | Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드 |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| WO2021241802A1 (ko) * | 2020-05-26 | 2021-12-02 | 올릭스 주식회사 | 연결 조직 성장 인자를 표적으로 하는 RNAi 제제 및 이의 용도 |
| WO2021242883A1 (en) | 2020-05-26 | 2021-12-02 | University Of Massachusetts | Synthetic oligonucleotides having regions of block and cluster modifications |
| WO2021257782A1 (en) | 2020-06-18 | 2021-12-23 | Alnylam Pharmaceuticals, Inc. | XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| CN117677699A (zh) | 2021-06-23 | 2024-03-08 | 马萨诸塞大学 | 用于治疗先兆子痫和其他血管生成病症的优化抗flt1寡核苷酸化合物 |
| WO2023117738A1 (en) | 2021-12-20 | 2023-06-29 | F. Hoffmann-La Roche Ag | Threose nucleic acid antisense oligonucleotides and methods thereof |
| CN120615125A (zh) * | 2022-07-27 | 2025-09-09 | e-生物有限公司 | 核酸化合物 |
| AU2023313030A1 (en) * | 2022-07-27 | 2025-01-09 | E-Therapeutics Plc | Nucleic acid compounds |
| EP4332221A1 (en) | 2022-08-29 | 2024-03-06 | Roche Innovation Center Copenhagen A/S | Threose nucleic acid antisense oligonucleotides and methods thereof |
| WO2024126654A1 (en) | 2022-12-14 | 2024-06-20 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting actl6b |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5270030A (en) | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| JP3131222B2 (ja) | 1991-12-24 | 2001-01-31 | アイシス・ファーマシューティカルス・インコーポレーテッド | ギャップを有する２′修飾オリゴヌクレオチド |
| EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US20050032067A1 (en) | 2002-11-05 | 2005-02-10 | Prakash Thazha P. | Non-phosphorous-linked oligomeric compounds and their use in gene modulation |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| ES2234563T5 (es) | 1999-02-12 | 2018-01-17 | Daiichi Sankyo Company, Limited | Nuevos análogos de nucleósidos y oligonucleótidos |
| WO2000049035A1 (en) | 1999-02-19 | 2000-08-24 | The General Hospital Corporation | Gene silencing |
| KR20070118315A (ko) | 1999-04-21 | 2007-12-14 | 와이어쓰 | 폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물 |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| WO2001036641A2 (en) | 1999-11-02 | 2001-05-25 | Chiron Corporation | DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| WO2001066475A1 (en) | 2000-03-08 | 2001-09-13 | Kyong-Ho Engineering & Architects Co., Ltd. | Apparatus and method for purifying wastewater |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| CA2429814C (en) * | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| US20040063654A1 (en) | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
| EP1445312B1 (en) | 2001-11-21 | 2012-12-26 | Astellas Pharma Inc. | Method of inhibiting gene expression |
| DE60310944T3 (de) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Weitere neue formen von interferierende rns moleküle |
| ATE443765T1 (de) | 2003-03-21 | 2009-10-15 | Santaris Pharma As | Analoga kurzer interferierender rna (sirna) |
| IL155561A0 (en) | 2003-04-24 | 2006-12-31 | Yeda Res & Dev | Oligonucleotides that block toll-like receptors |
| US20060058255A1 (en) * | 2004-03-01 | 2006-03-16 | Jianzhu Chen | RNAi-based therapeutics for allergic rhinitis and asthma |
| JP2007536253A (ja) * | 2004-05-04 | 2007-12-13 | ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド | 細胞内への核酸の送達を増強し、細胞中の標的遺伝子の発現を修飾するための組成物及び方法 |
| WO2005116204A1 (ja) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| US20060089324A1 (en) * | 2004-10-22 | 2006-04-27 | Sailen Barik | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
| WO2006047842A2 (en) | 2004-11-08 | 2006-05-11 | K.U. Leuven Research And Development | Modified nucleosides for rna interference |
| WO2007041218A2 (en) | 2005-09-30 | 2007-04-12 | Oklahoma Medical Research Foundation | Regulation of tool-like receptors on stem cells |
| EP1989307B1 (en) | 2006-02-08 | 2012-08-08 | Quark Pharmaceuticals, Inc. | NOVEL TANDEM siRNAS |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| US20100292301A1 (en) | 2007-02-28 | 2010-11-18 | Elena Feinstein | Novel sirna structures |
| JP2010527914A (ja) | 2007-04-26 | 2010-08-19 | クォーク ファーマシューティカルズ インコーポレーティッド | 呼吸器系への抑制性核酸分子の治療的送達 |
| WO2009000929A2 (en) | 2007-06-28 | 2008-12-31 | Opsona Therapeutics Limited | Composition and method for treatment of autoimmune disease |
| WO2009015107A1 (en) | 2007-07-20 | 2009-01-29 | Yeda Research And Development Co. Ltd. | Modulation of toll-like receptors for controlling neurogenesis |
| EP2170366B1 (en) * | 2007-08-03 | 2013-11-06 | Opsona Therapeutics Limited | Use of tlr-2 antagonists for treatment of reperfusion injury and tissue damage |
| RU2487716C2 (ru) | 2007-10-03 | 2013-07-20 | Кварк Фармасьютикалс, Инк. | Новые структуры малых интерферирующих рнк (sirna) |
| KR20110081336A (ko) * | 2008-11-04 | 2011-07-13 | 이데라 파마슈티칼즈, 인코포레이티드 | 안티센스 올리고누클레오티드에 의한 ｔｏｌｌ―유사 수용체 2 발현의 조절 |
| GB0908425D0 (en) * | 2009-05-15 | 2009-06-24 | Medical Res Council | Medical use |
| CN102458418B (zh) | 2009-06-08 | 2015-09-16 | 夸克制药公司 | 一种寡核苷酸化合物的制药用途 |
| US20140154783A1 (en) * | 2009-07-06 | 2014-06-05 | Alnylam Pharmaceuticals, Inc. | Bioprocessing |
| AU2010324658A1 (en) * | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
| WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
-
2012
- 2012-03-01 CA CA2828544A patent/CA2828544A1/en not_active Abandoned
- 2012-03-01 AU AU2012223366A patent/AU2012223366B2/en not_active Ceased
- 2012-03-01 SG SG2013066220A patent/SG193280A1/en unknown
- 2012-03-01 SG SG10201604479YA patent/SG10201604479YA/en unknown
- 2012-03-01 CN CN201280020460.XA patent/CN103562387A/zh active Pending
- 2012-03-01 WO PCT/US2012/027174 patent/WO2012118911A1/en not_active Ceased
- 2012-03-01 EP EP12708475.4A patent/EP2681315B1/en not_active Not-in-force
- 2012-03-01 US US14/002,901 patent/US9487778B2/en not_active Expired - Fee Related
- 2012-03-01 JP JP2013556834A patent/JP6132775B2/ja not_active Expired - Fee Related
-
2013
- 2013-09-02 IL IL228260A patent/IL228260B/en active IP Right Grant
-
2017
- 2017-04-17 JP JP2017081112A patent/JP6407347B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014509511A (ja) | 2014-04-21 |
| CA2828544A1 (en) | 2012-09-07 |
| AU2012223366A1 (en) | 2014-02-20 |
| EP2681315B1 (en) | 2017-05-03 |
| JP6407347B2 (ja) | 2018-10-17 |
| AU2012223366B2 (en) | 2017-02-23 |
| NZ614712A (en) | 2015-09-25 |
| JP2017148060A (ja) | 2017-08-31 |
| JP6132775B2 (ja) | 2017-05-24 |
| CN103562387A (zh) | 2014-02-05 |
| WO2012118911A1 (en) | 2012-09-07 |
| EP2681315A1 (en) | 2014-01-08 |
| IL228260B (en) | 2018-02-28 |
| NZ712025A (en) | 2017-03-31 |
| SG10201604479YA (en) | 2016-07-28 |
| US9487778B2 (en) | 2016-11-08 |
| US20140329878A1 (en) | 2014-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9487778B2 (en) | Oligonucleotide modulators of the toll-like receptor pathway | |
| US8859751B2 (en) | Oligonucleotide compounds comprising non-nucleotide overhangs | |
| CN102666856B (zh) | 定向至RhoA靶基因的双链RNA化合物在制造治疗神经性疼痛的药物中的用途 | |
| AU2012332517B9 (en) | Methods and compositions for neuroprotection | |
| US9796979B2 (en) | Oligonucleotide modulators of the toll-like receptor pathway | |
| NZ614712B2 (en) | Oligonucleotide modulators of the toll-like receptor pathway | |
| NZ712025B2 (en) | Oligonucleotide modulators of the toll-like receptor pathway | |
| DK2521783T3 (en) | OLIGONUCLEOTIDE COMPOUNDS INCLUDING NON-NUCLEOTIDE COVERAGE | |
| HK1178566B (en) | Oligonucleotide compounds comprising non-nucleotide overhangs |